These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

312 related articles for article (PubMed ID: 29508109)

  • 1. IL-6 signalling pathways and the development of type 2 diabetes.
    Akbari M; Hassan-Zadeh V
    Inflammopharmacology; 2018 Jun; 26(3):685-698. PubMed ID: 29508109
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Diabetes and branched-chain amino acids: What is the link?
    Bloomgarden Z
    J Diabetes; 2018 May; 10(5):350-352. PubMed ID: 29369529
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Recent advances in the relationship between obesity, inflammation, and insulin resistance.
    Bastard JP; Maachi M; Lagathu C; Kim MJ; Caron M; Vidal H; Capeau J; Feve B
    Eur Cytokine Netw; 2006 Mar; 17(1):4-12. PubMed ID: 16613757
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rosiglitazone increases matrix production and quenches inflammation: studies in human cells.
    Solini A; Santini E; Madec S; Nannipieri M; Bonotti A; Cuccato S; Ferrannini E
    Diabetes Metab Res Rev; 2008; 24(3):197-204. PubMed ID: 17922475
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hemin therapy suppresses inflammation and retroperitoneal adipocyte hypertrophy to improve glucose metabolism in obese rats co-morbid with insulin-resistant type-2 diabetes.
    Ndisang JF; Jadhav A
    Diabetes Obes Metab; 2013 Nov; 15(11):1029-39. PubMed ID: 23731386
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Spleen-Derived Anti-Inflammatory Cytokine IL-10 Stimulated by Adipose Tissue-Derived Stem Cells Protects Against Type 2 Diabetes.
    Zhang J; Deng Z; Jin L; Yang C; Liu J; Song H; Han W; Si Y
    Stem Cells Dev; 2017 Dec; 26(24):1749-1758. PubMed ID: 29032727
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of rosiglitazone and metformin on inflammatory markers and adipokines: decrease in interleukin-18 is an independent factor for the improvement of homeostasis model assessment-beta in type 2 diabetes mellitus.
    Kim HJ; Kang ES; Kim DJ; Kim SH; Ahn CW; Cha BS; Nam M; Chung CH; Lee KW; Nam CM; Lee HC
    Clin Endocrinol (Oxf); 2007 Feb; 66(2):282-9. PubMed ID: 17224000
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Experimental evidence for the use of CCR2 antagonists in the treatment of type 2 diabetes.
    Sullivan TJ; Miao Z; Zhao BN; Ertl LS; Wang Y; Krasinski A; Walters MJ; Powers JP; Dairaghi DJ; Baumgart T; Seitz LC; Berahovich RD; Schall TJ; Jaen JC
    Metabolism; 2013 Nov; 62(11):1623-32. PubMed ID: 23953944
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hitting a complex target: an update on interleukin-6 trans-signalling.
    Waetzig GH; Rose-John S
    Expert Opin Ther Targets; 2012 Feb; 16(2):225-36. PubMed ID: 22324903
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Physiological effects of modulating the interleukin-6 axis.
    Schett G
    Rheumatology (Oxford); 2018 Feb; 57(suppl_2):ii43-ii50. PubMed ID: 29982781
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Double stranded viral RNA induces inflammation and insulin resistance in skeletal muscle from pregnant women in vitro.
    Lappas M
    Metabolism; 2015 May; 64(5):642-53. PubMed ID: 25707553
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Role of E3 ubiquitin ligases in insulin resistance.
    Yang XD; Xiang DX; Yang YY
    Diabetes Obes Metab; 2016 Aug; 18(8):747-54. PubMed ID: 27097743
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The inflammatory status score including IL-6, TNF-α, osteopontin, fractalkine, MCP-1 and adiponectin underlies whole-body insulin resistance and hyperglycemia in type 2 diabetes mellitus.
    Daniele G; Guardado Mendoza R; Winnier D; Fiorentino TV; Pengou Z; Cornell J; Andreozzi F; Jenkinson C; Cersosimo E; Federici M; Tripathy D; Folli F
    Acta Diabetol; 2014 Feb; 51(1):123-31. PubMed ID: 24370923
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High glucose induces suppression of insulin signalling and apoptosis via upregulation of endogenous IL-1beta and suppressor of cytokine signalling-1 in mouse pancreatic beta cells.
    Venieratos PD; Drossopoulou GI; Kapodistria KD; Tsilibary EC; Kitsiou PV
    Cell Signal; 2010 May; 22(5):791-800. PubMed ID: 20067833
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Short-term infusion of interleukin-6 does not induce insulin resistance in vivo or impair insulin signalling in rats.
    Rotter Sopasakis V; Larsson BM; Johansson A; Holmäng A; Smith U
    Diabetologia; 2004 Nov; 47(11):1879-87. PubMed ID: 15551046
    [TBL] [Abstract][Full Text] [Related]  

  • 16. IL-6 in diabetes and cardiovascular complications.
    Qu D; Liu J; Lau CW; Huang Y
    Br J Pharmacol; 2014 Aug; 171(15):3595-603. PubMed ID: 24697653
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Apoptotic signal transduction pathways in diabetes.
    Mandrup-Poulsen T
    Biochem Pharmacol; 2003 Oct; 66(8):1433-40. PubMed ID: 14555218
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Interleukin-1 receptor antagonist improves normoglycemia and insulin sensitivity in diabetic Goto-Kakizaki-rats.
    Akash MS; Rehman K; Sun H; Chen S
    Eur J Pharmacol; 2013 Feb; 701(1-3):87-95. PubMed ID: 23348707
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Past and current perspective on new therapeutic targets for Type-II diabetes.
    Patil PD; Mahajan UB; Patil KR; Chaudhari S; Patil CR; Agrawal YO; Ojha S; Goyal SN
    Drug Des Devel Ther; 2017; 11():1567-1583. PubMed ID: 28579755
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting gp130 to prevent inflammation and promote insulin action.
    Kraakman MJ; Allen TL; Whitham M; Iliades P; Kammoun HL; Estevez E; Lancaster GI; Febbraio MA
    Diabetes Obes Metab; 2013 Sep; 15 Suppl 3():170-5. PubMed ID: 24003934
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.